



Report #:

IF-824-QSA-TR006-BTL26246-04

Page 1 of 2



Title:

Certificate of Analysis (CoA)

Date: 4/20/2026**Date Tested:****Customer:**

Apex Lab-BW Compounds

Testing material:**Lot Number:** BWC-S20-20202**BT Sample ID:** 005000039656140**Labeled Peptide****Content/Potency:** 20 mg**Storage:** R.T.**Visual Description:** Small clear vial: white sample, white label, silver crimp, white plastic cap.**Labeled as:** Semaglutide**Manufacturer:** N/A**Testing Purpose:** FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.

Test	Method	Specification	Result
General Appearance	USP <630>	white powder	white powder
Mass	USP <41>	As recorded	64.8 mg
FTIR Identification and Composition Analysis	USP <197A>	Sample spectrum should confirm the content of peptide via characteristic bands	FTIR sample spectrum confirms the presence of Semaglutide with addition of excipient(s)/fillers.
HPLC Purity of Peptide Assay	USP <621>	Specifications: $\geq 98\%$	99.8 %
HPLC Potency Assay	USP <621>	Specifications: 90 – 110% of 20 mg	20.1 mg (100.7 %)
Peptide-to-Excipients Ratio	USP <1151>	Recommended ratios of (1:2) to (1:10) for (peptide: excipients)	20.1 : 44.7 mg (1:2.2)

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

Andrea Castro, AS
Scientist-II
BTLabs

Verna Zheng, AS
Scientist-II
BTLabs

5730 Corporate Way | Suite 220 | West Palm Beach, FL 33407

Phone: (561) 625-0133


E-mail: info@btlabtesting.com | Website: <https://btlabtesting.com>

Title:


Certificate of Analysis (CoA)



FTIR ID and Composition Analysis: Semaglutide Lot BWC-S20-20202



HPLC Purity and Potency Assay @ 280 nm: Semaglutide Lot BWC-S20-20202



Semaglutide Lot BWC-S20-20202 @ 280 nm

Peak #:	Retention Time (min)	Area (mAU*s)
1	9.378	2784.7